A Phase 3 trial of eloralintide in people whose weight stays high on a weekly incretin is registered
Phase IIIP1Primary public evidenceTrial registry record
NCT07392190 lists a start date of 10 February 2026 for a Phase 3 placebo-controlled trial of once-weekly eloralintide in adults with persistent obesity or overweight who are already treated with a weekly incretin, with and without type 2 diabetes. The registry lists 900 planned participants, 185 locations and primary completion in June 2028.
900
Planned participants, as recorded in the registry
June 2028
Primary completion date listed in the registry
Background and context
What persistent means in the record
The record asks for adults on stable weekly incretin therapy who still have obesity (BMI 30 or more) or overweight with a related complication (BMI 27 or more). They take eloralintide or placebo on top of that treatment, with or without type 2 diabetes, and the primary endpoint is percent change in body weight at week 64.
Who is excluded
People with type 1 diabetes are excluded, as is recent use of DPP-4 inhibitors, amylin analogs or insulin. Participation lasts about 80 weeks.
What the record leaves out
The background treatment is described only as stable incretin therapy, and no products are named. No results are posted, so this entry says nothing about what eloralintide adds on top of an incretin.
Trial record: ClinicalTrials.gov NCT07392190, read on 2026-10-15. Registered plans can change.
P1Primary public evidenceTrial registry record.An official trial registration. A registration shows that a study exists; it does not show that the compound works.
